The NFATc2-inhibited xenografts showed more effective tumor inhibition (5.44 fold, 39.73 fold, respectively) compared to the control group (3.54 fold) (p<0.01) and differences in tumor volumes on the growth curve were statistically significant (Figure 4—figure supplement 3B–C). The gene discussed is NFATC2; the disease is neoplasm.